136 related articles for article (PubMed ID: 34071914)
1. Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin
Grob NM; Schibli R; Béhé M; Mindt TL
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071914
[TBL] [Abstract][Full Text] [Related]
2. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
[No Abstract] [Full Text] [Related]
4. Cholecystokinin 2 Receptor Agonist
Rottenburger C; Nicolas GP; McDougall L; Kaul F; Cachovan M; Vija AH; Schibli R; Geistlich S; Schumann A; Rau T; Glatz K; Behe M; Christ ER; Wild D
J Nucl Med; 2020 Apr; 61(4):520-526. PubMed ID: 31519804
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [
Grzmil M; Imobersteg S; Blanc A; Frank S; Schibli R; Béhé MP
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959437
[TBL] [Abstract][Full Text] [Related]
6. 1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs.
Grob NM; Schibli R; Béhé M; Valverde IE; Mindt TL
ACS Med Chem Lett; 2021 Apr; 12(4):585-592. PubMed ID: 33859799
[TBL] [Abstract][Full Text] [Related]
7. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
8. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
9. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.
Zavvar TS; Hörmann AA; Klingler M; Summer D; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37052226
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Actinium-225 Labeled Minigastrin Analogue [
Qin Y; Imobersteg S; Blanc A; Frank S; Schibli R; Béhé MP; Grzmil M
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33198403
[TBL] [Abstract][Full Text] [Related]
11. Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions.
Grob NM; Schmid S; Schibli R; Behe M; Mindt TL
J Med Chem; 2020 May; 63(9):4496-4505. PubMed ID: 32302130
[TBL] [Abstract][Full Text] [Related]
12. Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting.
Grob NM; Häussinger D; Deupi X; Schibli R; Behe M; Mindt TL
J Med Chem; 2020 May; 63(9):4484-4495. PubMed ID: 32302139
[TBL] [Abstract][Full Text] [Related]
13. Effect of
Hörmann AA; Klingler M; Rangger C; Mair C; Joosten L; Franssen GM; Laverman P; von Guggenberg E
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986657
[TBL] [Abstract][Full Text] [Related]
14. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
[TBL] [Abstract][Full Text] [Related]
16. In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [
Rottenburger C; Hentschel M; Fürstner M; McDougall L; Kottoros D; Kaul F; Mansi R; Fani M; Vija AH; Schibli R; Geistlich S; Behe M; Christ ER; Wild D
EJNMMI Res; 2024 Apr; 14(1):37. PubMed ID: 38581480
[TBL] [Abstract][Full Text] [Related]
17. Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties.
Kossatz S; Mansi R; Béhé M; Czerney P; Hilger I
EJNMMI Res; 2013 Nov; 3(1):75. PubMed ID: 24238262
[TBL] [Abstract][Full Text] [Related]
18. Development of the First
Günther T; Holzleitner N; Di Carlo D; Urtz-Urban N; Lapa C; Wester HJ
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986687
[TBL] [Abstract][Full Text] [Related]
19. Signaling Network Response to α-Particle-Targeted Therapy with the
Qin Y; Imobersteg S; Frank S; Blanc A; Chiorazzo T; Berger P; Schibli R; Béhé MP; Grzmil M
J Nucl Med; 2023 Jun; 64(6):873-879. PubMed ID: 36732057
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.
Klingler M; Rangger C; Summer D; Kaeopookum P; Decristoforo C; von Guggenberg E
Pharmaceuticals (Basel); 2019 Jan; 12(1):. PubMed ID: 30650563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
